Radiotherapy compliance is maintained with hyprofractionation and concurrent cetuximab in locally advanced head and neck cancer

被引：8
|
作者：
Chan, Andrew [1 ]
Teoh, Daien [1 ]
Singhera, Paul [1 ]
Hartley, Andrew [1 ]
机构：
[1] Queen Elizabeth Hosp, Ctr Canc, Birmingham B15 2TH, W Midlands, England
来源：
RADIOTHERAPY AND ONCOLOGY | 2009年 / 93卷 / 03期
关键词：
SQUAMOUS-CELL CARCINOMA;
D O I：
10.1016/j.radonc.2009.05.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：654 / 654
页数：1
相关论文
共 50 条
  • [1] Radiotherapy combined with Cetuximab for locally advanced head and neck cancer
    Acevedo-Henao, C-M
    Valette, G.
    Marianowski, R.
    Pradier, O.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 96 - 96
  • [2] Manageable Early Toxicity of Cetuximab Concurrent with Radical Radiotherapy for Locally Advanced Head and Neck Cancer
    Wieczorek, A.
    Hamid, A.
    O'Toole, L.
    CLINICAL ONCOLOGY, 2011, 23 (07) : 496 - 496
  • [3] Hypofractionated Radiotherapy plus Cetuximab in Locally Advanced Head and Neck Cancer
    Teoh, D. C.
    Rodger, S.
    Say, J.
    Hartley, A.
    CLINICAL ONCOLOGY, 2008, 20 (09) : 717 - 717
  • [4] Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
    Argiris, Athanassios
    Heron, Dwight E.
    Smith, Ryan P.
    Kim, Seungwon
    Gibson, Michael K.
    Lai, Stephen Y.
    Branstetter, Barton F.
    Posluszny, Donna M.
    Wang, Lin
    Seethala, Raja R.
    Dacic, Sanja
    Gooding, William
    Grandis, Jennifer R.
    Johnson, Jonas T.
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) : 5294 - 5300
  • [5] Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)
    Walsh, Lorraine
    Gillham, Charles
    Dunne, Mary
    Fraser, Ian
    Hollywood, Donal
    Armstrong, John
    Thirion, Pierre
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 (01) : 38 - 41
  • [6] Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer
    Strom, Tobin J.
    Trotti, Andy M.
    Kish, Julie
    Russell, Jeffery S.
    Rao, Nikhil G.
    McCaffrey, Judith
    Padhya, Tapan A.
    Otto, Kristen J.
    Caudell, Jimmy J.
    ORAL ONCOLOGY, 2015, 51 (07) : 704 - 708
  • [7] Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity
    Acevedo-Henao, C. M.
    Valette, G.
    Miglierini, P.
    Lefur, E.
    Pradier, O.
    CANCER RADIOTHERAPIE, 2012, 16 (07): : 601 - 603
  • [8] Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)
    Galper, S. L.
    Deshpande, H.
    Rose, M. G.
    Decker, R. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
    Ferris, Robert L.
    Moskovitz, Jessica
    Kunning, Sheryl
    Ruffin, Ayana T.
    Reeder, Carly
    Ohr, James
    Gooding, William E.
    Kim, Seungwon
    Karlovits, Brian J.
    Vignali, Dario A. A.
    Duvvuri, Umamaheswar
    Johnson, Jonas T.
    Petro, Daniel
    Heron, Dwight E.
    Clump, David A.
    Bruno, Tullia C.
    Bauman, Julie E.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1335 - 1344
  • [10] Cetuximab, cisplatin and amifostine during accelerated radiotherapy for locally advanced head and neck cancer
    Tsoutsou, P. G.
    Danielidis, V.
    Koukourakis, M. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345